ABSTRACT

Radiopharmaceuticals can be successfully applied in nuclear medicine for the diagnosis and treatment of various diseases, especially cancer. As a result of combining of radiopharmaceuticals with nanotechnology, the design of nanosized therapeutic drug delivery systems in healthcare has been a preferred approach in preclinical and clinical studies for at least twenty years. Nanosized drug formulations play a large role in cancer diagnosis and treatment and have several advantages over other conventional chemotherapeutic drug delivery systems. This review describes the current state or clinical application potential of recently developed radionuclide-containing drug delivery systems in preclinical and clinical research, including the design and modifications of these systems and radiolabeling approaches.